PDCD1 and non-small cell lung carcinoma: One trial (NCT02793856) studying the therapeutic effect of knocking out the programmed cell death protein 1 (PD-1) in patient derived T-cells via NHEJ in refractory non-small-cell lung cancer, found a good ratio of 48.7 of on-target over off-target editing.